Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Strs Ohio

Strs Ohio lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 27.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,735 shares of the medical equipment provider’s stock after selling 81,589 shares during the period. Strs Ohio’s holdings in Zimmer Biomet were worth $21,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in ZBH. Dodge & Cox increased its stake in Zimmer Biomet by 12.9% during the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after acquiring an additional 2,533,009 shares during the last quarter. Norges Bank purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth $225,867,000. AQR Capital Management LLC increased its position in shares of Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after purchasing an additional 955,284 shares during the last quarter. Franklin Resources Inc. raised its holdings in Zimmer Biomet by 15.2% in the 2nd quarter. Franklin Resources Inc. now owns 4,673,860 shares of the medical equipment provider’s stock valued at $426,303,000 after buying an additional 615,014 shares during the period. Finally, Invesco Ltd. lifted its position in Zimmer Biomet by 11.5% in the second quarter. Invesco Ltd. now owns 4,606,591 shares of the medical equipment provider’s stock valued at $420,167,000 after buying an additional 475,921 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $86.55 on Friday. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The firm has a market cap of $17.15 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 2.21 and a beta of 0.62. The company’s 50 day moving average is $91.34 and its two-hundred day moving average is $96.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a research report on Thursday, January 8th. Citigroup lowered their price objective on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. Barclays dropped their target price on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target on the stock. in a research note on Friday, January 9th. Finally, Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $107.33.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.